kalgene pharmaceuticals
CEO, Dr. T. Nathan Yoganathan
The National Research Council of Canada (NRC) has granted KalGene Pharmaceuticals an exclusive worldwide license for a therapeutic molecule against Alzheimer's disease. The molecule targets amyloid beta plaques, which are abnormal clusters of protein fragments that build up between brain nerve cells. These clusters are considered prime suspects in the development and progression of Alzheimer’s disease.
KalGene believes that coupling the NRC’s molecule with its proprietary carriers could enable the development of a disease modifying drug to fight Alzheimer’s disease.